Research advances of nanoknife ablation combined with programmed death-1/programmed death ligand-1 in treatment of pancreatic cancer and relative immunological mechanisms / 中国介入影像与治疗学

ABSTRACT

Although the special tumor microenvironment of pancreatic cancer is not conducive to immunotherapy, nanoknife ablation can partial reverse immunosuppression, therefore is the only way of ablation for pancreatic cancer. Results of animal studies showed that the treatment of pancreatic cancer with nanoknife ablation combined with programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) might prolong the survival time. The research advances of the mechanisms of nanoknife ablation combined with PD-1/PD-L1 in treatment of pancreatic cancer and the relative immunological mechanisms were reviewed in this article.